Loading…
REGENERON PHARMACEUTICALS, INC.
Basic Materials · Pharmaceutical Preparations
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $8.9B | $4.7B | $4.0B | $4.0B | $3.6B |
| Net Income |
Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.
| $8.1B |
| $4.3B |
| $4.0B |
| $4.4B |
| $4.5B |
| Diluted EPS | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 |
| Operating Cash Flow | $7.1B | $5.0B | $4.6B | $4.4B | $5.0B |
| Free Cash Flow | — | — | — | — | — |